January 30, 2013 News Archive

The endoscopy company expects target market segment to continue growing at rapid rate.

The software is targeted specifically at prostate cancer.

Company gets the new year rolling with trial to treat uncontrolled hypertension.

Reports are trickling out of unexpected effects of excise tax.

Appointee also will serve on the board.

The implants are intended to treat chronic back and leg pain.

After an unsatisfactory close to 2012, company trims the fat.

News » 2013 » January » Wednesday the 30th